#Hemoglobin concentration and risk of arterial and venous #thrombosis in 1.5 million Swedish and Danish blood donors

..The risk of myocardial infarction and ischemic stroke increased with higher hemoglobin concentration in both men and women. The HRs for myocardial infarction and ischemic stroke in men with hemoglobin concentration ≥ 17.5 g/dL were 3.52 (95% confidence interval [CI], 2.85–4.36) and 2.36 (95% CI, 1.63–3.43), respectively, compared to the reference group. The corresponding HRs for women with hemoglobin concentration ≥ 16.0 g/dL were 3.22 (2.12–4.89) and 2.35 (1.37–4.02) for myocardial … Continue reading #Hemoglobin concentration and risk of arterial and venous #thrombosis in 1.5 million Swedish and Danish blood donors

Safety and efficacy of high-dose unfractionated #heparin versus high-dose enoxaparin for venous #thromboembolism prevention in morbidly obese hospitalized patients

..A single-center retrospective observational study was conducted in morbidly obese (body mass index ≥ 40 kg/m2) hospitalized patients who received either high-fixed dose enoxaparin (40 mg every 12 hours) or unfractionated heparin (7,500 units every 8 hours) for venous thromboembolism prophylaxis. ..In the 305 patients included (n=190 unfractionated heparin, n=115 enoxaparin), the incidence of major bleeding was significantly higher in the unfractionated heparin group (OR … Continue reading Safety and efficacy of high-dose unfractionated #heparin versus high-dose enoxaparin for venous #thromboembolism prevention in morbidly obese hospitalized patients

#THROMBOEMBOLIC RISK IN MEDICAL PATIENT: AN EXTENSIVE REVIEW AND FUTURE PERSPECTIVES

..Many studies have proven relevant reduction of fatal pulmonary embolism due to improved medical practice aimed to provide proper thromboembolic prophylactic therapy. RESULTS: Despite scientific efforts in clinical prevention, influence of some patients demographic variables are often underestimated (i.e. older age..) and real burden of absolute venous thromboembolic risk and thromboprophylactic efficacy remain unclear. Moreover, establishment and development of Emergency and Acute Care Departments select … Continue reading #THROMBOEMBOLIC RISK IN MEDICAL PATIENT: AN EXTENSIVE REVIEW AND FUTURE PERSPECTIVES

#Rivaroxaban Versus Vitamin K Antagonist in #Antiphospholipid Syndrome: A Randomized Noninferiority Trial

After 3 years of follow-up, recurrent thrombosis occurred in 11 patients (11.6%) in the rivaroxaban group and 6 (6.3%) in the VKA group (RR in the rivaroxaban group, 1.83 [95% CI, 0.71 to 4.76]). Stroke occurred more commonly in patients receiving rivaroxaban (9 events) than in those receiving VKAs (0 events) (corrected RR, 19.00 [CI, 1.12 to 321.9]). Major bleeding occurred in 6 patients (6.3%) … Continue reading #Rivaroxaban Versus Vitamin K Antagonist in #Antiphospholipid Syndrome: A Randomized Noninferiority Trial